1.
2.
3.
4.
5.
6.
7.
Panula, P. et al. International union of basic and clinical pharmacology. XCVIII. histamine receptors. Pharmacol. Rev. 67,
601–655 (2015).
Ash, A. S. F. & Schild, H. O. Receptors mediating some actions of
histamine. Br. J. Pharmacol. Chemother. 27, 427–439 (1966).
Black, J. W., Duncan, W. A. M., Durant, C. J., Ganellin, C. R. & Parsons, E. M. Definition and antagonism of histamine H2-Receptors.
Nature 236, 385–390 (1972).
Thurmond, R. L. The histamine H4 receptor: From orphan to the
clinic. Front. Pharmacol. 6, 1–11 (2015).
Arrang, J. M., Garbarg, M. & Schwartz, J. C. Auto-inhibition of brain
histamine release mediated by a novel class (H3) of histamine
receptor. Nature 302, 832–837 (1983).
Lovenberg, T. W. et al. Cloning and functional expression of the
human histamine H3 receptor. Mol. Pharmacol. 55,
1101–1107 (1999).
Schwartz, J. C. The histamine H3 receptor: From discovery to clinical trials with pitolisant. Br. J. Pharmacol. 163, 713–721 (2011).
Article
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
Oda, T., Morikawa, N., Saito, Y., Masuho, Y. & Matsumoto, S. I.
Molecular cloning and characterization of a novel type of histamine
receptor preferentially expressed in leukocytes. J. Biol. Chem. 275,
36781–36786 (2000).
Nakamura, T., Itadani, H., Hidaka, Y., Ohta, M. & Tanaka, K. Molecular
cloning and characterization of a new human histamine receptor,
HH4R. Biochem. Biophys. Res. Commun. 279, 615–620 (2000).
Liu, C. et al. Cloning and pharmacological characterization of a
fourth histamine receptor (H4) expressed in bone marrow. Mol.
Pharmacol. 59, 420–426 (2001).
Morse, K. L. et al. Cloning and characterization of a novel human
histamine receptor. J. Pharmacol. Exp. Ther. 296, 1058–1066 (2001).
Nguyen, T. et al. Discovery of a novel member of the histamine
receptor family. Mol. Pharmacol. 59, 427–433 (2001).
Gutzmer, R. Pathogenetic and therapeutic implications of the histamine H4 receptor in inflammatory skin diseases and pruritus.
Front. Biosci. S3, 985 (2011).
Cramp, S. et al. Identification and hit-to-lead exploration of a novel
series of histamine H4 receptor inverse agonists. Bioorganic Med.
Chem. Lett. 20, 2516–2519 (2010).
Marson, C. M. Targeting the histamine H4 receptor. Chem. Rev. 111,
7121–7156 (2011).
Zampeli, E. & Tiligada, E. The role of histamine H 4 receptor in
immune and inflammatory disorders. British J. Pharmacol. 157,
24–33 (2009).
Sadek, B. & Stark, H. Cherry-picked ligands at histamine receptor
subtypes. Neuropharmacology 106, 56–73 (2016).
Corrêa, M. F. & Fernandes, J. P. D. S. Histamine H4 receptor ligands:
Future applications and state of art. Chem. Biol. Drug Des. 85,
461–480 (2015).
Shimamura, T. et al. Structure of the human histamine H 1 receptor
complex with doxepin. Nature 475, 65–72 (2011).
Xia, R. et al. Cryo-EM structure of the human histamine H1 receptor/
Gq complex. Nat. Commun. 12, 1–9 (2021).
Inoue, A. et al. Illuminating G-protein-coupling selectivity of GPCRs.
Cell 177, 1933–1947.e25 (2019).
Rasmussen, S. G. F. et al. Crystal structure of the β2 adrenergic
receptor–Gs protein complex. Nat. 2011 4777366 477,
549–555 (2011).
Maeda, S. et al. Development of an antibody fragment that stabilizes GPCR/G-protein complexes. Nat. Commun. 9, (2018).
Inoue, A. et al. TGFα shedding assay: An accurate and versatile
method for detecting GPCR activation. Nat. Methods 9,
1021–1029 (2012).
Michino, M. et al. What can crystal structures of aminergic receptors tell us about designing subtype-selective ligands? Pharmacol.
Rev. 67, 198–213 (2015).
Zhuang, Y. et al. Structural insights into the human D1 and D2
dopamine receptor signaling complexes. Cell 184,
931–942.e18 (2021).
Im, D. et al. Structure of the dopamine D2 receptor in complex with
the antipsychotic drug spiperone. Nat. Commun. 11, 1–11 (2020).
Kooistra, A. J., Kuhne, S., De Esch, I. J. P., Leurs, R. & De Graaf, C. A
structural chemogenomics analysis of aminergic GPCRs: Lessons
for histamine receptor ligand design. Br. J. Pharmacol. 170,
101–126 (2013).
Jongejan, A. et al. Delineation of agonist binding to the human
histamine H4 receptor using mutational analysis, homology modeling, and ab initio calculations. J. Chem. Inf. Model. 48,
1455–1463 (2008).
Shin, N. et al. Molecular modeling and site-specific mutagenesis of
the histamine-binding site of the histamine H4 receptor. Mol.
Pharmacol. 62, 38–47 (2002).
Lim, H. D. et al. Molecular determinants of ligand binding to H4R
species variants. Mol. Pharmacol. 77, 734–743 (2010).
Nature Communications | (2023)14:6538
https://doi.org/10.1038/s41467-023-42260-z
32. van der Goot, H., Schepers, M., Sterk, G. & Timmerman, H. Isothiourea analogues of histamine as potent agonists or antagonists of
the histamine H3-receptor. Eur. J. Med. Chem. 27, 511–517 (1992).
33. Garbarg, M. et al. S-[2-(4-imidazolyl)ethyl]isothiourea, a highly
specific and potent histamine H3 receptor agonist.J. Pharmacol.
Exp. Ther. 263, 304–310 (1992).
34. Mehta, P. et al. Enigmatic histamine receptor h4 for potential
treatment of multiple inflammatory, autoimmune, and related diseases. Life 10, (2020).
35. Feng, Z., Hou, T. & Li, Y. Docking and MD study of histamine H4R
based on the crystal structure of H1R. J. Mol. Graph. Model. 39,
1–12 (2013).
36. Schultes, S. et al. Mapping histamine H4 receptor-ligand binding
modes. Medchemcomm 4, 193–204 (2013).
37. Katritch, V., Cherezov, V. & Stevens, R. C. Structure-function of the
G protein-coupled receptor superfamily. Annu. Rev. Pharmacol.
Toxicol. 53, 531–556 (2013).
38. Filipek, S. Molecular switches in GPCRs. Curr. Opin. Struct. Biol. 55,
114–120 (2019).
39. Robertson, M. J. et al. Structure determination of inactive-state
GPCRs with a universal nanobody. Nat. Struct. Mol. Biol. 29,
1188–1195 (2022).
40. Peng, X. et al. Structural basis for recognition of antihistamine drug
by human histamine receptor. Nat. Commun. 13, (2022).
41. Jablonowski, J. A. et al. The first potent and selective non-imidazole
human histamine H4 receptor antagonists. J. Med. Chem. 46,
3957–3960 (2003).
42. Rosethorne, E. M. & Charlton, S. J. Agonist-biased signalling at the
histamine H4 receptor: JNJ7777120 recruits beta-arrestin without
activating G proteins. Mol. Pharmacol. 79, 749–757 (2010).
43. Nijmeijer, S. et al. Detailed analysis of biased histamine H4 receptor
signalling by JNJ 7777120 analogues. Br. J. Pharmacol. 170,
78–88 (2013).
44. Thurmond, R. L. et al. Clinical and preclinical characterization of the
histamine H(4) receptor antagonist JNJ-39758979. J. Pharmacol.
Exp. Ther. 349, 176–184 (2014).
45. Murata, Y. et al. Phase 2a, randomized, double-blind, placebocontrolled, multicenter, parallel-group study of a H4 R-antagonist
(JNJ-39758979) in Japanese adults with moderate atopic dermatitis.
J. Dermatol. 42, 129–139 (2015).
46. Wifling, D. et al. Molecular determinants for the high constitutive
activity of the human histamine H4 receptor: Functional studies on
orthologues and mutants. Br. J. Pharmacol. 172, 785–798 (2015).
47. Chun, E. et al. Fusion partner toolchest for the stabilization and
crystallization of G protein-coupled receptors. Structure 20,
967–976 (2012).
48. Nehmea, R. et al. Mini-G proteins: Novel tools for studying GPCRs in
their active conformation. PLoS One 12, 1–26 (2017).
49. Carpenter, B., Nehmé, R., Warne, T., Leslie, A. G. W. & Tate, C. G.
Structure of the adenosine A2A receptor bound to an engineered G
protein. Nature 536, 104–107 (2016).
50. Liang, Y. L. et al. Dominant negative g proteins enhance formation
and purification of agonist-gpcr-g protein complexes for structure
determination. ACS Pharmacol. Transl. Sci. 1, 12–20 (2018).
51. Kim, K. et al. Structure of a hallucinogen-activated Gq-coupled
5-HT2A serotonin receptor. Cell 182, 1574–1588.e19 (2020).
52. Maeda, S., Qu, Q., Robertson, M. J., Skiniotis, G. & Kobilka, B. K.
Structures of the M1 and M2 muscarinic acetylcholine receptor/Gprotein complexes. Science (80-.). 364, 552–557 (2019).
53. Wang, Y. et al. Molecular recognition of an acyl-peptide hormone
and activation of ghrelin receptor. Nat. Commun. 12, 5064
(2021).
54. Duan, J. et al. Cryo-EM structure of an activated VIP1 receptor-G
protein complex revealed by a NanoBiT tethering strategy. Nat.
Commun. 11, 1–10 (2020).
10
Article
55. Mastronarde, D. N. Automated electron microscope tomography
using robust prediction of specimen movements. J. Struct. Biol. 152,
36–51 (2005).
56. Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. CryoSPARC: Algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).
57. Bepler, T., Kelley, K., Noble, A. J. & Berger, B. Topaz-Denoise: general deep denoising models for cryoEM and cryoET. Nat. Commun.
11, 1–12 (2020).
58. Wagner, T. et al. SPHIRE-crYOLO is a fast and accurate fully automated particle picker for cryo-EM. Commun. Biol. 2, 1–13 (2019).
59. Punjani, A., Zhang, H. & Fleet, D. J. Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction.
Nat. Methods 17, 1214–1221 (2020).
60. Terwilliger, T. C., Sobolev, O. V., Afonine, P. V. & Adams, P. D.
Automated map sharpening by maximization of detail and connectivity. Acta Crystallogr. Sect. D Struct. Biol. 74, 545–559 (2018).
61. Adams, P. D. et al. PHENIX: A comprehensive Python-based system
for macromolecular structure solution. Acta Crystallogr. Sect. D
Biol. Crystallogr. 66, 213–221 (2010).
62. Yamashita, K., Palmer, C. M., Burnley, T. & Murshudov, G. N. CryoEM single-particle structure refinement and map calculation using
Servalcat. Acta Crystallogr. Sect. D Struct. Biol. 77, 1282–1291 (2021).
63. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and
development of Coot. Acta Crystallogr. Sect. D Biol. Crystallogr. 66,
486–501 (2010).
64. Afonine, P. V. et al. Real-space refinement in PHENIX for cryo-EM
and crystallography. Acta Crystallogr. Sect. D Struct. Biol. 74,
531–544 (2018).
65. Goddard, T. D. et al. UCSF ChimeraX: Meeting modern challenges
in visualization and analysis. Protein Sci. 27, 14–25 (2018).
66. Friesner, R. A. et al. Glide: A New Approach for Rapid, Accurate
Docking and Scoring. 1. Method and Assessment of Docking
Accuracy. J. Med. Chem. 47, 1739–1749 (2004).
Acknowledgements
This work was supported by a Grant-in-Aid from the Japanese Ministry of
Education, Culture, Sports, Science and Technology (19H00923 (S.I.)
and 23K06357 (D.I.)) and the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug
Discovery and Life Science Research (BINDS)) from Japan Agency for
Medical Research and Development (AMED) under the grant number
JP21am0101079 and JP23ama121007 (S.I.). This study was also supported by the Takeda Science Foundation and the Mochida Memorial
Foundation for Medical and Pharmaceutical Research (D.I.). This work
was performed in part under the Collaborative Research Program as the
Visiting Fellow of Institute for Protein Research, Osaka University,
VFCR–23-02 (S.I.) and in part using the cryo-electron microscope under
Nature Communications | (2023)14:6538
https://doi.org/10.1038/s41467-023-42260-z
the Collaborative Research Program of Institute for Protein Research,
Osaka University, CEMCR-23-02 (H.A.).
Author contributions
D.I., H.A., and S.I. designed the experiments. D.I. prepared the cryo-EM
samples, and Y. Shiimura helped with the construction of Gq-heterotrimer expression. D.I., J.K., Y.F.F., Y. Sugita, T.N., T.K., and H.A. performed the cryo-EM analysis. H.H., A.I., and H.A. performed the TGFα
shedding assay. D.I., H.A., and S.I. wrote the paper with assistance from
all of the authors. T.K., H.A., and S.I. supervised the project. All authors
have read and approved the final version of the manuscript.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information The online version contains
supplementary material available at
https://doi.org/10.1038/s41467-023-42260-z.
Correspondence and requests for materials should be addressed to
Takayuki Kato, Hidetsugu Asada or So Iwata.
Peer review information Nature Communications thanks Javier GarciaNafria and the other, anonymous, reviewer(s) for their contribution to the
peer review of this work. A peer review file is available.
Reprints and permissions information is available at
http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2023
11
...
論文の公開元へ
